Novo Nordisk to slash prices of weightloss drugs in US / Photo: SCOTT OLSON - GETTY IMAGES NORTH AMERICA/AFP/File
-
Arteta hails Arsenal's desire after perfect start to title defence
-
TikTok to pay $400 mn settlement in US children's privacy case
-
Betis down Real Sociedad in La Liga opener
-
MLS fines Messi for striking an opponent
-
Mexican governor resumes job despite US drug charges
-
Gouiri double fires Marseille past Strasbourg in Ligue 1 opener
-
Arsenal rout Coventry to open Premier League season in style
-
Mavericks buy out Thompson, now reportedly bound for Heat
-
Giant-killer Bejlek overhauls Keys to reach Cincinnati semi-finals
-
England v Pakistan first Test: Three talking points
-
Man Utd agree deal for Brighton midfielder Baleba: reports
-
US, Canada push to seal trade deal as deadline nears
-
Werro wins Lausanne 800m, well off world record pace
-
One dead, three wounded after sword attack at Swedish high school
-
China mulls bid to host 2028 UN climate talks: sources
-
Ukraine says 'cynical' Russian strike on shopping centre killed 15
-
Jones becomes third Englishman to join Inter this summer
-
US Supreme Court allows White House ballroom construction for now
-
Mexican governor wanted on US drug charges returns to job
-
Root hails emerging fast bowlers as England thrash Pakistan
-
Bolivia's Paz forced to fire economy minister in mid-crisis
-
Brazil's Lula urges tariffs resolution in call with Trump
-
A-Rod ups T-Wolves stake in $4.5bn ownership change
-
Ukraine says 'cynical' Russian strike on shopping centre killed 14
-
UK court orders Prince Harry, others to pay Daily Mail initial £9.5mn
-
Heatwave-hit Europe logs over 30,000 excess summer deaths: first figures
-
'Grateful' ex-world champion Alaphilippe retires from cycling
-
Give LIV Golf 'one more shot,' says DeChambeau
-
US, Canada work to wrap up trade deal ahead of looming deadline
-
Duplantis hits the high notes for athletics anthem
-
Malaysia's JDT claim unbeaten run world record
-
Malaysia's JDT claims unbeaten run world record
-
At least 2 teens seriously wounded in sword attack at Swedish school
-
Bolivian economy minister fired after Congress vote
-
Popular forest near Paris to reopen after wildfire
-
Russell roars to Dutch GP sprint pole, Antonelli fifth
-
UN holds second informal poll of secretary-general candidates
-
Russell takes pole for Dutch GP sprint
-
Shakhtar Donetsk to play Champions League home games at Chelsea
-
England start life after Bazball with rout of Pakistan
-
Arsenal sign Villa centre-back Konsa as champions bolster defence
-
'Duck run' pest control catching on in S.Africa's winelands
-
The 'hedgehogs' leading Poland's defences on Russian border
-
UK, Canada, Australia slam Israel ending probe into aid worker killings
-
England thrash Pakistan by an innings and 103 runs in first Test
-
Spurs spending spree vital to raise standards: De Zerbi
-
Fury says Joshua fight 'doesn't look like it's going to happen'
-
US, Canada try to wrap up trade deal before latest Trump deadline
-
Argentina's Paredes suspended 10 matches by FIFA for World Cup fight
-
World No.1 Sinner withdraws from US Open with knee injury
Novo Nordisk to slash prices of weightloss drugs in US
Danish drugmaker Novo Nordisk, which is struggling with competition for its anti-obesity treatments, said Tuesday that it will sharply cut prices for its flagship drugs in the US, announcing a 50 percent cut for Wegovy and 35 percent for Ozempic.
"This decision applies to all doses of these medicines and reflects Novo Nordisk's commitment to enhancing affordability for patients and both public and private payers dealing with the complexities of the evolving US healthcare system," the company said in a statement.
Effective January 1, 2027, the list price will be $675 for a month's worth of Wegovy, which currently costs around $1,350 a month.
Ozempic and Rybelsus, treatments that each currently come to about $1,000, will also be priced $675.
Novo Nordisk said the price reduction is meant to make it possible to reach more patients.
"Lowering the list price of Wegovy and Ozempic is the best approach to address the unprecedented opportunity to help more than 100 million people living with obesity and over 35 million people with type 2 diabetes in the United States," Jamey Millar, executive vice president of Novo Nordisk's US Operations, said.
In early February, Novo Nordisk vowed legal against US chain Hims & Hers for offering a copycat of the new pill version of Wegovy.
Limited production capacity for the blockbuster drug led the FDA to temporarily allow pharmacies to create so-called "compound" or copycat versions of Wegovy and Ozempic, an analogue used to treat diabetes.
That authorisation expired last May 22 but Novo Nordisk has complained of copycat versions of its drugs still being available.
Ozempic is an injectable anti-diabetic treatment that became popular on social media for its slimming properties.
Wegovy, which has the same active ingredient as Ozempic in a different dose, is a weight-loss drug and is also available in pill form.
Both treatments use analogues of the hormone GLP-1, which regulates blood glucose levels and appetite.
Shares in Novo Nordisk have taken a beating in recent weeks after it warned in early February of lower sales revenue in the United States as intensified competition pushes down prices.
They fell 3.8 percent in afternoon trading in Copenhagen.
T.Perez--AT